HRP20180678T1 - Spojevi [1,2,4]triazol[1,5-c]kinazolin-5-amina supstituirani s heterobiciklom pogodni za liječenje ili prevenciju poremećaja središnjeg živčanog sustava - Google Patents
Spojevi [1,2,4]triazol[1,5-c]kinazolin-5-amina supstituirani s heterobiciklom pogodni za liječenje ili prevenciju poremećaja središnjeg živčanog sustavaInfo
- Publication number
- HRP20180678T1 HRP20180678T1 HRP20180678TT HRP20180678T HRP20180678T1 HR P20180678 T1 HRP20180678 T1 HR P20180678T1 HR P20180678T T HRP20180678T T HR P20180678TT HR P20180678 T HRP20180678 T HR P20180678T HR P20180678 T1 HRP20180678 T1 HR P20180678T1
- Authority
- HR
- Croatia
- Prior art keywords
- heterobicycle
- quinazoline
- triazole
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/087865 WO2014101120A1 (en) | 2012-12-28 | 2012-12-28 | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| PCT/CN2013/076853 WO2014101373A1 (en) | 2012-12-28 | 2013-06-06 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder |
| PCT/US2013/076781 WO2014105666A1 (en) | 2012-12-28 | 2013-12-20 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| EP13866588.0A EP2945632B1 (en) | 2012-12-28 | 2013-12-20 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180678T1 true HRP20180678T1 (hr) | 2018-06-01 |
Family
ID=51019745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180678TT HRP20180678T1 (hr) | 2012-12-28 | 2013-12-20 | Spojevi [1,2,4]triazol[1,5-c]kinazolin-5-amina supstituirani s heterobiciklom pogodni za liječenje ili prevenciju poremećaja središnjeg živčanog sustava |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9708347B2 (enExample) |
| EP (1) | EP2945632B1 (enExample) |
| JP (1) | JP6306049B2 (enExample) |
| KR (1) | KR102165113B1 (enExample) |
| AU (1) | AU2013370977B2 (enExample) |
| BR (1) | BR112015015468B8 (enExample) |
| CA (1) | CA2896056C (enExample) |
| CY (1) | CY1120258T1 (enExample) |
| DK (1) | DK2945632T3 (enExample) |
| ES (1) | ES2667477T3 (enExample) |
| HR (1) | HRP20180678T1 (enExample) |
| HU (1) | HUE037950T2 (enExample) |
| LT (1) | LT2945632T (enExample) |
| ME (1) | ME03034B (enExample) |
| MX (1) | MX370017B (enExample) |
| NO (1) | NO2945632T3 (enExample) |
| PL (1) | PL2945632T3 (enExample) |
| PT (1) | PT2945632T (enExample) |
| RS (1) | RS57162B1 (enExample) |
| RU (2) | RU2018136104A (enExample) |
| SI (1) | SI2945632T1 (enExample) |
| WO (3) | WO2014101120A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10138212B2 (en) | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
| US10688082B2 (en) | 2015-06-11 | 2020-06-23 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
| WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| WO2017034990A1 (en) * | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity |
| EP3337788A4 (en) | 2015-08-21 | 2019-03-27 | Portola Pharmaceuticals, Inc. | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE |
| US10821106B2 (en) | 2015-08-21 | 2020-11-03 | Srx Cardio, Llc | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2017107087A1 (en) * | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2017112719A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018130184A1 (zh) | 2017-01-13 | 2018-07-19 | 江苏恒瑞医药股份有限公司 | 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 |
| EP3587419A4 (en) | 2017-02-27 | 2020-08-05 | Betta Pharmaceuticals Co., Ltd. | FGFR INHIBITOR AND APPLICATION OF IT |
| EP3575301A4 (en) | 2017-03-16 | 2020-08-05 | Jiangsu Hengrui Medicine Co., Ltd. | HETEROARYL [4,3-C] PYRIMIDINE-5-AMINE DERIVATIVE, PROCESS FOR PREPARATION AND MEDICAL USES |
| SG11202002886PA (en) * | 2017-09-28 | 2020-04-29 | Cstone Pharmaceuticals Suzhou Co Ltd | Fused ring derivative as a2a receptor inhibitor |
| WO2019118313A1 (en) | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties |
| US20210032253A1 (en) | 2018-02-06 | 2021-02-04 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof |
| CA3119774A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| EP3883576B1 (en) | 2018-11-20 | 2025-12-17 | Merck Sharp & Dohme LLC | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| WO2020112706A1 (en) | 2018-11-30 | 2020-06-04 | Merck Sharp & Dohme Corp. | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
| TW202039496A (zh) | 2018-11-30 | 2020-11-01 | 美商默沙東藥廠 | 做為腺苷受體拮抗劑之9-經取代胺基三唑喹唑啉衍生物、醫藥組合物及其用途 |
| KR20210114963A (ko) | 2019-01-11 | 2021-09-24 | 오메로스 코포레이션 | 암을 치료하기 위한 방법 및 조성물 |
| AR117844A1 (es) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
| EP3785734B1 (en) | 2019-03-26 | 2023-04-12 | Novel Pharma Inc. | Long-acting fatty acid-binding gnrh derivative and pharmaceutical composition comprising same |
| TWI901639B (zh) | 2020-02-07 | 2025-10-21 | 美商迦舒布魯姆生物有限公司 | 雜環glp-1促效劑 |
| EP4185296A4 (en) * | 2020-07-24 | 2025-03-05 | Merck Sharp & Dohme LLC | DUAL ADENOSINE A2A RECEPTOR AND A2B RECEPTOR ANTAGONISTS FOR IMMUNO-ONCOLOGY |
| WO2022020552A1 (en) * | 2020-07-24 | 2022-01-27 | Merck Sharp & Dohme Corp. | Adenosine a2a and a2b receptor dual antagonists for immuno-oncology |
| CN112159411A (zh) * | 2020-10-15 | 2021-01-01 | 南京工业大学 | 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| CA3256033A1 (en) | 2022-04-13 | 2023-10-19 | Arcus Biosciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2 |
| CN120957993A (zh) | 2023-02-16 | 2025-11-14 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0181282A1 (de) * | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazolochinazolinverbindungen |
| US4713383A (en) * | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| AU7237294A (en) * | 1993-07-27 | 1995-02-28 | Kyowa Hakko Kogyo Co. Ltd. | Remedy for parkinson's disease |
| WO1995035107A1 (en) | 1994-06-20 | 1995-12-28 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US5571775A (en) * | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US5929106A (en) | 1997-10-27 | 1999-07-27 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP1283839B1 (en) | 2000-05-26 | 2005-04-20 | Schering Corporation | Adenosine a2a receptor antagonists |
| AU2001274287A1 (en) | 2000-06-20 | 2002-01-02 | Nour Eddin Ajan Alhadid | Electrical drive line |
| US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| DE60335294D1 (de) * | 2002-12-19 | 2011-01-20 | Schering Corp | Dlung des extrapyramidalen syndroms |
| ATE418555T1 (de) * | 2003-04-09 | 2009-01-15 | Biogen Idec Inc | A2a-adenosinrezeptorantagonisten |
| NZ542823A (en) * | 2003-04-23 | 2009-03-31 | Schering Corp | 2-Alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
| AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
| ATE457988T1 (de) | 2006-06-26 | 2010-03-15 | Schering Corp | A2a-adenosin-rezeptor-antagonisten |
| US20090062253A1 (en) * | 2007-08-31 | 2009-03-05 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| EP2509983B1 (en) * | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
-
2012
- 2012-12-28 WO PCT/CN2012/087865 patent/WO2014101120A1/en not_active Ceased
-
2013
- 2013-06-06 WO PCT/CN2013/076853 patent/WO2014101373A1/en not_active Ceased
- 2013-12-20 PL PL13866588T patent/PL2945632T3/pl unknown
- 2013-12-20 ES ES13866588.0T patent/ES2667477T3/es active Active
- 2013-12-20 RU RU2018136104A patent/RU2018136104A/ru unknown
- 2013-12-20 HU HUE13866588A patent/HUE037950T2/hu unknown
- 2013-12-20 AU AU2013370977A patent/AU2013370977B2/en not_active Ceased
- 2013-12-20 PT PT138665880T patent/PT2945632T/pt unknown
- 2013-12-20 WO PCT/US2013/076781 patent/WO2014105666A1/en not_active Ceased
- 2013-12-20 RS RS20180410A patent/RS57162B1/sr unknown
- 2013-12-20 JP JP2015550682A patent/JP6306049B2/ja not_active Expired - Fee Related
- 2013-12-20 SI SI201330980T patent/SI2945632T1/en unknown
- 2013-12-20 US US14/655,648 patent/US9708347B2/en active Active
- 2013-12-20 DK DK13866588.0T patent/DK2945632T3/en active
- 2013-12-20 EP EP13866588.0A patent/EP2945632B1/en active Active
- 2013-12-20 LT LTEP13866588.0T patent/LT2945632T/lt unknown
- 2013-12-20 NO NO13866588A patent/NO2945632T3/no unknown
- 2013-12-20 MX MX2015008481A patent/MX370017B/es active IP Right Grant
- 2013-12-20 BR BR112015015468A patent/BR112015015468B8/pt not_active IP Right Cessation
- 2013-12-20 HR HRP20180678TT patent/HRP20180678T1/hr unknown
- 2013-12-20 RU RU2015131148A patent/RU2671628C2/ru active
- 2013-12-20 ME MEP-2018-97A patent/ME03034B/me unknown
- 2013-12-20 CA CA2896056A patent/CA2896056C/en active Active
- 2013-12-20 KR KR1020157020147A patent/KR102165113B1/ko not_active Expired - Fee Related
-
2017
- 2017-02-02 US US15/423,238 patent/US10011615B2/en active Active
-
2018
- 2018-05-04 CY CY20181100472T patent/CY1120258T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180678T1 (hr) | Spojevi [1,2,4]triazol[1,5-c]kinazolin-5-amina supstituirani s heterobiciklom pogodni za liječenje ili prevenciju poremećaja središnjeg živčanog sustava | |
| BR112013021366A2 (pt) | imidazo[5,1-f][1,2,4]triazinas para o tratamento de desordens neurológicas | |
| BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
| CL2016003145A1 (es) | Compuestos de [1,2,4]triazol sustituido | |
| PL2822555T3 (pl) | Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu | |
| WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
| EA201591689A1 (ru) | НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ,ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3 | |
| ZA201607736B (en) | Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors | |
| PT2838539T (pt) | Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos. | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| SI2935274T1 (sl) | 3-okso-2,3,5,8-tetrahidro-(1,2,4)triazolo(4,3-a)pirimidinski derivati za zdravljenje bolezni dihal | |
| ZA201401678B (en) | Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| HRP20181481T1 (hr) | D-metadon za liječenje psihijatrijskih simptoma | |
| HUS2000037I1 (hu) | Triazinok Protozoa okozta betegségek kezelésére | |
| WO2013185048A3 (en) | Heterocyclic guanidine f1f0-atpase inhibitors | |
| DK3083627T3 (da) | [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis | |
| SMT201600395B (it) | Derivati di pantotenato per il trattamento di disturbi neurologici | |
| IL238415B (en) | Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e | |
| PL392436A1 (pl) | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego | |
| EP2914270A4 (en) | MEDIUM TO AVOID OR IMPROVE RECOVERIES OF THE BRAIN FUNCTION | |
| IL244619A0 (en) | Pyrido[3-b,4]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| EP2994156A4 (en) | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity | |
| PL395469A1 (pl) | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego | |
| EP2914257A4 (en) | MEDIUM TO AVOID OR IMPROVE RECOVERIES OF THE BRAIN FUNCTION |